drugset / Trial / NCT01576718
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate (50, 100, 200, and 400mcg) delivered as Fluticasone Spiromax® Inhalation Powder (Fp Spiromax) when administered twice daily in subjects 12 years of age and older with severe persistent asthma who are uncontrolled on high dose ICS therapy.
Timeline
- Start
- 2012-04
- Primary completion
- 2013-07
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluticasone propionate | Other / unclassified | 50 ug | Inhaled |
| Subject | Fluticasone propionate | Other / unclassified | 100 ug | Inhaled |
| Subject | Fluticasone propionate | Other / unclassified | 200 ug | Inhaled |
| Subject | Fluticasone propionate | Other / unclassified | 250 ug | Inhaled |
| Subject | Fluticasone propionate | Other / unclassified | 400 ug | Inhaled |
| Background | Salbutamol | Unknown | 90 ug | Inhaled |